Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px
Document › Details

Nanobiotix S.A.. (1/16/19). "Press Release: Nanobiotix Plans to Conduct Registered Public Offering in the United States". Paris & Cambridge, MA.

Region Region United States (USA)
Organisations Organisation Nanobiotix S.A. (Euronext Paris: NANO)
  Group Nanobiotix (Group)
  Organisation 2 Securities and Exchange Commission (SEC) (US)
  Group United States (govt)
Products Product investment banking
  Product 2 nanomedicine
Index term Index term Nanobiotix–SEVERAL: investment, 201901– filing of Form F-1 for registered public offering of shares + ADSs in US conditions to be determined later
Persons Person Gaubert, Sarah (Nanobiotix 201603 Head Communication + Public Affairs)
  Person 2 Janic, Marion (RooneyPartners 201702 Partner joined 2008)
     


NANOBIOTIX SA (Euronext : NANO – ISIN : FR0011341205) announced today that it plans to conduct a registered public offering of its ordinary shares, including in the form of American Depositary Shares (ADSs) in the United States, and has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission. The timing, number of new ordinary shares and ADSs to be issued, the price of such shares and ADSs, and the other terms of the proposed offering have not yet been determined.

This announcement is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933. This press release does not, and is not intended to, constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.


***


About NANOBIOTIX

Incorporated in 2003, Nanobiotix is a late clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Company’s headquarters are based in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany.


Contacts Nanobiotix

Sarah Gaubert Director, Communication & Public Affairs +33 (0)1 40 26 07 55 sarah.gaubert@nanobiotix.com / contact@nanobiotix.com

Noël Kurdi Director, Investor Relations +1 (646) 241-4400 noel.kurdi@nanobiotix.com / investors@nanobiotix.com

Ricky Bhajun Investor Relations Europe +33 (0)1 79 97 29 99 ricky.bhajun@nanobiotix.com / investors@nanobiotix.com

Media relations

France - Springbok Consultants Marina Rosoff +33 (0)6 71 58 00 34 marina@springbok.fr

United States – RooneyPartners Marion Janic +1 (212) 223-4017 mjanic@rooneyco.com

   
Record changed: 2019-01-22

Advertisement

Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 600x80px

More documents for Nanobiotix (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top